The purpose of this study is to determine whether Bipolar I Disorder refractory treatment with Quetiapine monotherapy could be better potentiated with Lithium or Aripiprazole. The investigators hypothesized that Lithium or Aripiprazole would provide similar compliance and tolerability in maintenance treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
50
Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
Institute of Psychiatry, University of São Paulo
São Paulo, São Paulo, Brazil
RECRUITINGInstitute of Psychiatry
São Paulo, São Paulo, Brazil
RECRUITINGThe main outcome will be the number of patients that achieve and remain in remission to each treatment at the end of each phase of the study
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.